Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome by Low Dose Cytosine Arabinoside
Recent reports by Baccarani and Tura , Moloney and Rosenthal , and Housset et al.  prompted us to treat 12 acute myeloid leukemia (AML) and 4 myelodysplastic Syndrome (MDS) patients with low dose cytosine arabinoside (Ara-C). In all patients, conventional chemotherapy was contraindicated because of previous inefficacy, advanced age, or heavy comorbidity. Ara-C was given in a dose of 10 mg/m2 s. c. every 12 h for 14–28 days. All patients received one or two courses. If bone marrow revealed more than 5% blasts 1 week after the end of therapy, another course was started. Patients who obtained a complete or partial remission received maintenance chemotherapy with low dose Ara-C (10 mg/m2 s. c. every 12 h) for 8 days every 3 or 4 weeks.
KeywordsAcute Myeloid Leukemia Polycythemia Vera Cytosine Arabinoside Bone Marrow Hypoplasia Arabinosyl Cytosine
Unable to display preview. Download preview PDF.
- 9.Moloney WC, Rosenthal DS (1981) Treatment of early acute nonlymphatic leukemia with low-dose cytosine arabinoside. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern trends in human leukemia IV. Springer, Berlin Heidelberg New York, pp 59–62Google Scholar
- 12.Solal-Celigny P, Desaint B, Herrera A, Chastang C, Amar M, Vroclans M, Brousse N, Mancilla F, Renoux M, Bernard JF, Boivin P (1984) Chronic myelomonocytic leukemia according to FAB Classification: analysis of 35 cases. Blood 53: 634Google Scholar
- 13.Wisch JS, Griffin JD, Kufe DW (1983) Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599 62Google Scholar